CompletedPhase 1NCT05308953
A Phase I Safety Study of NVG-291 in Healthy Adults
Studying Spinal cord injury
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NervGen Pharma
- Principal Investigator
- Daniel Miko, MDCMO
- Intervention
- NVG-291(drug)
- Enrollment
- 74 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2021 – 2023
Study locations (1)
- Nucleus Networks, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05308953 on ClinicalTrials.govOther trials for Spinal cord injury
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06410001CE-STAND: Cervical Epidural STimulation After Neurologic DamageUniversity of Minnesota
- RECRUITINGNANCT07204184Multisite Transspinal Stimulation for Augmenting Recovery in Spinal Cord InjuryMaria Knikou, PT, MBA, PhD
- RECRUITINGNANCT06924177UTSW NORC Pilot Spinal Cord Injury Dietary ProgramUniversity of Texas Southwestern Medical Center
- RECRUITINGNANCT06867809Spine and Brain Stimulation for Movement Recovery After Cervical Spinal Cord InjuryJason Carmel
- ENROLLING BY INVITATIONNANCT06873776Arm and Leg Cycling for Accelerated SCI RecoveryShirley Ryan AbilityLab
- RECRUITINGNANCT07135583Non-Invasive Interventions for Respiratory Recovery in Chronic Spinal Cord InjuryThomas Jefferson University
- RECRUITINGNANCT07222033Self-balancing Personal Exoskeleton for SCI (WINY)Wandercraft
- RECRUITINGPHASE1, PHASE2NCT06677229Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord InjuryTechnophage, SA